Platelet activating factor levels and metabolism in tangier disease: A case study

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Kolovou, Vana ^a,b   Papakonstantinou, Vasiliki D ^b   Stamatakis, George ^b   Verouti, Sophia N ^b   Xanthopoulou, Marianna N ^c   Kolovou, Genovefa ^a   Demopoulos, Constantinos A ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c HAROKOPIO UNIVERSITY   (Greece)

Author keywords

Atherosclerosis; Lp PLA2; Lyso PAF AT; PAF; PAF AH; PAF CPT; Tangier Disease

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACYLTRANSFERASE; CHOLINEPHOSPHOTRANSFERASE; LIPOPROTEIN PHOSPHOLIPASE A2; PHOSPHOLIPASE A2; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ACETYLTRANSFERASE; THROMBOCYTE ACTIVATING FACTOR CHOLINEPHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CASE REPORT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; IN VITRO STUDY; LEUKOCYTE; LIPID BLOOD LEVEL; LIPID METABOLISM; NONHUMAN; RABBIT; TANGIER DISEASE; THROMBOCYTE RICH PLASMA;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLTRANSFERASES; ADENOSINE DIPHOSPHATE; ADULT; AGED; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL ASSAY; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; FEMALE; HUMANS; MIDDLE AGED; MUTATION; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; RABBITS; REFERENCE VALUES; TANGIER DISEASE; THROMBIN;

ORYCTOLAGUS CUNICULUS;

EID: 84863492240     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-89     Document Type: Article

References (46)

1. Tangier disease. Combined clinical staff conference at the National Institutes of Health. Fredrickson DS, Altrocehi PH, Avioli LV, Goodman DWS, Goodman HC, Ann Intern Med 1961 55 1016 1031
2. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J, Hayden MR, Nat Genet 1999 22 336 345 10.1038/11905 10431236 (Pubitemid 29369523)
3. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfle P, Assmann G, Nat Genet 1999 22 352 355 10.1038/11921 10431238 (Pubitemid 29369525)
4. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Bodzioch M, Orsá E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch- Ozcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G, Nat Genet 1999 22 347 351 10.1038/11914 10431237 (Pubitemid 29369524)
5. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, Kaminski WE, Schmitz G, Biochem Biophys Res Commun 1999 257 29 33 10.1006/bbrc.1999.0406 10092505 (Pubitemid 29299042)
6. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. Bortnick AE, Rothblat GH, Stoudt G, Hoppe KL, Royer LJ, McNeish J, Francone OL, J Biol Chem 2000 275 28634 28640 10893411
7. Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1. Oram JF, Trends Mol Med 2002 168 173 Review
8. Tangier disease four decades of research: a reflection of the importance of HDL. Kolovou GD, Mikhailidis DP, Anagnostopoulou KK, Daskalopoulou SS, Cokkinos DV, Curr Med Chem 2006 13 771 782 Review 10.2174/092986706776055580 16611066
9. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E, J Lipid Res 2003 44 1381 1386 10.1194/jlr.M300086-JLR200 12730297 (Pubitemid 37279620)
10. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl- 3-phosphorylcholine as tha active component (a new class of lipid chemical mediators). Demopoulos CA, Pinckard RN, Hanahan DJ, J Biol Chem 1979 254 9355 9358 489536 (Pubitemid 10248704)
11. Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells: relevance to the inflammatory reaction in atherogenesis. Dentan C, Lesnik P, Chapman MJ, Ninio E, Eur J Biochem 1996 236 48 55 10.1111/j.1432-1033.1996. 00048.x 8617285 (Pubitemid 26074859)
12. Platelet activating factor- A molecular link between atherosclerosis theories. Demopoulos CA, Karantonis HC, Antonopoulou S, Eur J Lipid Sci Tech 2003 105 705 716 10.1002/ejlt.200300845 (Pubitemid 37533028)
13. Food ingredients and lipid mediators. Nomikos T, Fragopoulou E, Antonopoulou S, Curr Nutr Food Sci 2007 3 255 276 (Pubitemid 350130928)
14. Biology of platelet-activating factor acetyhydrolase (PAF-AH), lipoprotein-associated phospholipase A2. Stafforini DM, Cardiovasc Drugs Ther 2009 223 73 83
15. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetyhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Detopoulou P, Nomikos T, Fragopoulou E, Panagiotakos DB, Pitsavos C, Stefanadis C, Antonopoulou S, Lipidis in Health and Disease 2009 8 19 10.1186/1476-511X-8-19
16. Tangier disease with unusual clinical manifestations. Kolovou GD, Wade DP, Sengupta R, Cokkinos DV, Clin Genet 2003 63 323 324 10.1034/j.1399-0004. 2003.00056.x 12702168 (Pubitemid 36949941)
17. A new ABCA1 mutation associated with low HDL cholesterol but without coronary artery disease. Kolovou G, Anagnostopoulou K, Cokkinos DV, Atherosclerosis 2003 169 345 346 10.1016/S0021-9150(03)00151-5 12921988 (Pubitemid 37297483)
18. Postprandial hypertriglyceridaemia in patients with Tangier disease. Kolovou G, Daskalova D, Anagnostopoulou K, Hoursalas I, Voudris V, Mikhailidis DP, Cokkinos DV, J Clin Pathol 2003 56 937 941 10.1136/jcp.56.12.937 14645354 (Pubitemid 37533238)
19. In Vitro and In Vivo Effects of Statins on Platelet-Activating Factor and Its Metabolism. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, Demopoulos CA, Angiology 2011 62 209 218 10.1177/0003319710375089 20805097
20. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? Tsoupras AB, Chini M, Tsogas N, et al. AIDS Res Hum Retroviruses 2008 24 1079 1086 10.1089/aid.2007.0263 18620493
21. In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. Karantonis HC, Antonopoulou S, Perrea DN, Sokolis DP, Theocharis SE, Kavantzas N, Iliopoulos DG, Demopoulos CA, Nutr Metab Cardiovasc Dis 2006 16 174 185 10.1016/j.numecd.2005.07.003 16580585
22. Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration. Tsantila N, Karantonis HC, Perrea DN, Theocharis SE, Iliopoulos DG, Iatrou C, Antonopoulou S, Demopoulos CA, Nutr Metab Cardiovasc Dis 2010 20 740 747 10.1016/j.numecd.2009.06.008 19748252
23. A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Demopoulos CA, Andrikopoulos NK, Antonopoulou S, Lipids 1994 29 305 309 10.1007/BF02536336 8177023 (Pubitemid 24113155)
24. A rapid method of total lipid extraction and purification. Bligh EG, Dyer WJ, Canadian Journal of Biochemistry and Physiology 1959 37 911 917 10.1139/o59-099 13671378
25. Platelet-activating-factor acetylhydrolase (Paf-Ah) in human kidney. Antonopoulou S, Demopoulos CA, Iatrou C, Moustakas G, Zirogiannis P, Int J Biochem 1994 26 1157 1162 10.1016/0020-711X(94)90138-4 7988740
26. Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDTinsensitive cholinephosphotransferase, of human mesangial cells. Tsoupras AB, Fragopoulou E, Nomikos T, Iatrou C, Antonopoulou S, Demopoulos CA, Mediators Inflam 2007 2007 276 283
27. Platelet-activating factor levels of serum and gingival crevicular fluid in nonsmoking patients with periodontitis and/or coronary heart disease. Chen H, Zheng P, Zhu H, Zhu J, Zhao L, El Mokhtari NE, Eberhard J, Lins M, Jepsen S, Clin Oral Investig 2010 14 629 636 10.1007/s00784-009-0346-5 19826843
28. Hydroxyl-platelet-activating factor exists in blood of healthy volunteers and periodontal patients. Antonopoulou S, Tsoupras A, Baltas G, Kotsifaki H, Mantzavinos Z, Demopoulos CA, Mediators Inflamm 2003 12 221 227 10.1080/09629350310001599666 14514473 (Pubitemid 37297191)
29. Periodontal parameters and platelet-activating factor levels in serum and gingival crevicular fluid in a Chinese population. Zheng P, Chen H, Shi S, Jepsen S, Eberhard J, J Clin Periodontol 2006 33 797 802 10.1111/j.1600-051X. 2006.00987.x 16970624 (Pubitemid 44511030)
30. The levels of platelet-activating factor and nitric oxide synthase in bronchial asthma at high altitude [Article in Chinese]. Gao F, Liu L, Li F, Zhonghua Jie He He Hu Xi Za Zhi 2010 33 578 581 20979844
31. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, Simons FE, Simons KJ, Cass D, Yeung J, N Engl J Med 2008 358 28 35 10.1056/NEJMoa070030 18172172
32. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Detopoulou P, Nomikos T, Fragopoulou E, Antonopoulou S, Kotroyiannis I, Vassiliadou C, Panagiotakos DB, Chrysohoou C, Pitsavos C, Stefanadis C, Clin Biochem 2009 42 44 49 10.1016/j.clinbiochem.2008.09.113 18955040
33. Quantitative analysis of platelet-activating factor in human plasma. Application to patients with liver cirrhosis and disseminated intravascular coagulation. Sugatani J, Miwa M, Komiyama Y, Murakami T, J Immunol Methods 1993 166 251 261 10.1016/0022-1759(93)90366-F 8288878
34. The degradation of Platelet-Activating Factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier Disease). Pritchard PH, Chonn A, Yeung CCH, Blood 1985 66 1476 1478 4063532 (Pubitemid 16194720)
35. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM, Proc Natl Acad Sci 1989 86 2393 2397 10.1073/pnas.86.7.2393 2928339 (Pubitemid 19102515)
36. Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance [Article in Chinese]. Wan DH, Fan P, Bai H, Song Q, Liu HW, Zhonghua Fu Chan Ke Za Zhi 2010 45 30 34 20367923
37. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Khovidhunkit W, Memon RA, Shigenaga JK, Pang M, Schambelan M, Mulligan K, Feingold KR, Grunfeld C, Metabolism 1999 48 1524 1531 10.1016/S0026-0495(99) 90240-8 10599983
38. Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease. Goudevenos J, Tselepis AD, Tsoukatos D, Grekas G, Kritikakos J, Sideris D, Eur Heart J 1995 16 1036 1043 8665964
39. Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Takamatsu S, Takamatsu M, Prostaglandins 1989 37 673 682 10.1016/0090-6980(89)90104-4 2772220 (Pubitemid 19202653)
40. Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis. Rufail ML, Schenkein HA, Barbour SE, Tew JG, van Antwerpen R, J Lipid Res 2005 46 2752 2760 10.1194/jlr.M500389- JLR200 16179738 (Pubitemid 43107488)
41. Lipoprotein-associated phospholipase A2 and plasma lipids in patients with destructive periodontal disease. Lösche W, Marshal GJ, Apatzidou DA, Krause S, Kocher T, Kinane DF, J Clin Periodontol 2005 32 640 644 10.1111/j.1600-051X.2005.00725.x 15882224 (Pubitemid 40780233)
42. Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. Serebruany VL, Gurbel PA, Murugesan SR, Lowry DR, Sturm E, Svetlov SI, Cardiology 1998 90 127 130 10.1159/000006831 9778550 (Pubitemid 28486689)
43. Normal values of PAF-induced platelet aggregation in healthy individuals. Stathopoulou R, Kafalas A, Mantas J, Demopoulos CA, Sparos L, Hippokrates 1990 3 119 124
44. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. Tselepis AD, Goudevenos JA, Tambaki AP, Michalis L, Stroumbis CS, Tsoukatos DC, Elisaf M, Sideris DA, Cardiovasc Res 1999 43 183 191 10.1016/S0008-6363(99)00078-4 10536703 (Pubitemid 29322878)
45. Abnormal platelet response to PAF and ADP in beta-thalassaemia. Demopoulos CA, Andrikopoulos NK, Stathopoulou-Sparou R, Int J Biochem 1988 20 599 604 10.1016/0020-711X(88)90099-7 3391336
46. Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. Harmon JT, Tandon NN, Hoeg JM, Jamieson GA, Blood 1986 68 498 505 3524709 (Pubitemid 16050675)